- Page 1 and 2: Health Evidence Review Commission's
- Page 3 and 4: AGENDA VALUE-BASED BENEFITS SUBCOMM
- Page 5 and 6: Value-based Benefits Subcommittee R
- Page 7 and 8: VALUE-BASED BENEFITS SUBCOMMITTEE C
- Page 9 and 10: ‣ Topic: Barrett’s esophagus Di
- Page 11 and 12: 7) Remove M42.1 (Adult osteochondro
- Page 13 and 14: Recommended Actions: 1) Add CPT 225
- Page 15 and 16: 6) Modify DIAGNOSTIC GUIDELINE D4,
- Page 17 and 18: tumor, benign brain and malignant b
- Page 19 and 20: Appendix A Revised Guideline Notes
- Page 21 and 22: Appendix A Revised Guideline Notes
- Page 23 and 24: Appendix B New Guideline Notes GUID
- Page 25 and 26: Section 2.0 Staff Report
- Page 27 and 28: 12) Removed G0458 (Low dose rate (l
- Page 29: Straightforward Issues—March, 201
- Page 33 and 34: Vitamin A Deficiencies Issue: sever
- Page 35 and 36: 2018 Biennial Review Merging Select
- Page 37 and 38: have similar prioritization (i.e. a
- Page 39 and 40: 296 ADRENAL OR CUTANEOUS HEMORRHAGE
- Page 41 and 42: Section 5.0 Previously Discussed It
- Page 43 and 44: HERC staff recommendations: 1) Add
- Page 45 and 46: 5D showed no difference in any of t
- Page 47 and 48: . The usefulness of emergent angiop
- Page 49 and 50: Endovascular stent insertion for in
- Page 51 and 52: Endovascular stent insertion for in
- Page 53 and 54: Endovascular stent insertion for in
- Page 55 and 56: T h e n e w e ngl a nd j o u r na l
- Page 57 and 58: Endovascular Management of Intracra
- Page 59 and 60: Balloon Dilation of Intracranial Va
- Page 61 and 62: Balloon Dilation of Intracranial Va
- Page 63 and 64: Downloaded from http://jnis.bmj.com
- Page 65 and 66: Neurocrit Care (2011) 15:336-341 DO
- Page 67 and 68: Endovascular stent insertion for in
- Page 69 and 70: Endovascular stent insertion for in
- Page 71 and 72: Endovascular stent insertion for in
- Page 73 and 74: Authors’ conclusions At present t
- Page 75 and 76: Breast/Chest Surgery Requirements f
- Page 77 and 78: add laser hair removal due to the n
- Page 79 and 80: Based on your interpretation of the
- Page 81 and 82:
Issue 6: A patient has contacted th
- Page 83 and 84:
Mammoplasty (CPT 19316, 19324-19325
- Page 85 and 86:
HERC staff recommendations: 1) Modi
- Page 87 and 88:
Mammoplasty (CPT 19316, 19324-19325
- Page 89 and 90:
Gender-affirming Vaginoplasty Danie
- Page 91 and 92:
Also, being severely overweight inc
- Page 93 and 94:
most of the surgery was in this are
- Page 95:
Letters of Support for Gender-affir
- Page 98 and 99:
or one letter with two signatures i
- Page 100 and 101:
is known as a transwoman; and the i
- Page 102 and 103:
• liposuction • mastopexy • n
- Page 104 and 105:
58573 Laparoscopy, surgical, with t
- Page 106 and 107:
21127 Augmentation, mandibular body
- Page 108 and 109:
Such operating subsidiaries include
- Page 110 and 111:
Gender Reassignment Surgery D. Age
- Page 112 and 113:
Gender Reassignment Surgery number
- Page 114 and 115:
Gender Reassignment Surgery 15775 P
- Page 116 and 117:
Gender Reassignment Surgery June 30
- Page 118 and 119:
Acupuncture for Tobacco Cessation Q
- Page 120 and 121:
Evidence: 1) White 2014 i , Cochran
- Page 122 and 123:
especially acupuncture combined wit
- Page 124 and 125:
HERC staff summary Four meta-analys
- Page 126 and 127:
Acupuncture and related interventio
- Page 128 and 129:
Main results We included 38 studies
- Page 130 and 131:
The American Journal of Chinese Med
- Page 132 and 133:
CLINICAL RESEARCH STUDY Alternative
- Page 134 and 135:
Current guideline note: GUIDELINE N
- Page 136 and 137:
. Patient has a wound classified as
- Page 138 and 139:
National Coverage Determination (NC
- Page 140 and 141:
National Coverage Determination (NC
- Page 142 and 143:
Section 7.0 New Discussion Items
- Page 144 and 145:
From Dr. Ruscher I am a Pediatric S
- Page 146 and 147:
Evidence—pectus excavatum 1) de O
- Page 148 and 149:
d. Exercise capacity or other patie
- Page 150 and 151:
Other policies 1) NICE 2009 a. Curr
- Page 152 and 153:
spurt. (Goretsky, 2004) Requests fo
- Page 154 and 155:
HERC staff recommendations: 1) Keep
- Page 156 and 157:
Disposition of submitted literature
- Page 158 and 159:
Data collection and analysis Two re
- Page 160 and 161:
Cardiac Function Before and After S
- Page 162 and 163:
European Journal of Cardio-thoracic
- Page 164 and 165:
The American Journal of Surgery (20
- Page 166:
Normalized cardiopulmonary exercise
- Page 169 and 170:
Journal of Pediatric Surgery (2005)
- Page 172 and 173:
REVIEW C URRENT OPINION Pectus cari
- Page 174 and 175:
Journal of Pediatric Surgery 50 (20
- Page 176 and 177:
Placement of pectus bar for pectus
- Page 178 and 179:
Placement of pectus bar for pectus
- Page 180 and 181:
Placement of pectus bar for pectus
- Page 182 and 183:
CIGNA covers surgical repair of pec
- Page 184 and 185:
optimal age for surgical repair is
- Page 186 and 187:
Professional Societies/Organization
- Page 188 and 189:
http://www.plasticsurgery.org/medic
- Page 190 and 191:
36. Liu SL, Li L, Cheng W, Hou WY,
- Page 192 and 193:
Pectus Excavatum and Poland's Syndr
- Page 194 and 195:
Pectus Excavatum and Poland's Syndr
- Page 196 and 197:
Pectus Excavatum and Poland's Syndr
- Page 198 and 199:
Pectus Excavatum and Poland's Syndr
- Page 200 and 201:
Pectus Excavatum and Poland's Syndr
- Page 202 and 203:
Pectus Excavatum and Poland's Syndr
- Page 204 and 205:
growth and subsequently require sur
- Page 206 and 207:
650 Bae et al controversial, but do
- Page 208 and 209:
652 Bae et al capacity of adults wh
- Page 210:
Telemedicine for Retinopathy of Pre
- Page 214 and 215:
impact on stroke recurrence (Afzal
- Page 216 and 217:
hypertrophic cardiomyopathy, and ar
- Page 218 and 219:
Downloaded from http://heart.bmj.co
- Page 220 and 221:
Cardiac Event Monitors file://dhs.s
- Page 222 and 223:
Cardiac Event Monitors file://dhs.s
- Page 224 and 225:
Cardiac Event Monitors file://dhs.s
- Page 226 and 227:
Cardiac Event Monitors file://dhs.s
- Page 228 and 229:
Cardiac Event Monitors file://dhs.s
- Page 230 and 231:
Cardiac Event Monitors file://dhs.s
- Page 232 and 233:
Cardiac Event Monitors file://dhs.s
- Page 234 and 235:
Cardiac Event Monitors file://dhs.s
- Page 236 and 237:
Cardiac Event Monitors file://dhs.s
- Page 238 and 239:
Cardiac Event Monitors file://dhs.s
- Page 240 and 241:
Cigna Medical Coverage Policy Subje
- Page 242 and 243:
• long-term continuous 48- to 21-
- Page 244 and 245:
Literature Review Continuous 24- to
- Page 246 and 247:
(46/56) of the patients were receiv
- Page 248 and 249:
presymptom memory loop recorders (a
- Page 250 and 251:
Covered when medically necessary to
- Page 252 and 253:
patient selected events transmitted
- Page 254 and 255:
19. Joshi AK, Kowey PR, Prystowsky
- Page 256 and 257:
46. U.S. Food and Drug Administrati
- Page 258 and 259:
Electric Tumor Treatment Fields for
- Page 260 and 261:
10) Industry sponsored trial Major
- Page 262 and 263:
d. Essential Health Benefit (EHB) d
- Page 264 and 265:
h. Wisconsin - up to 35 units of PT
- Page 266 and 267:
Appendix A Diagnoses which appear o
- Page 268 and 269:
t. 99468-99480 NICU/PICU 2) Service
- Page 270 and 271:
In any event, the proposed quantita
- Page 272 and 273:
March 2, 2016 Via Email: Darren.d.c
- Page 274 and 275:
Mr. Darren Coffman Director, Health
- Page 276 and 277:
Section 8.0 Coverage Guidances
- Page 278 and 279:
Background - Skin Ulcers • Common
- Page 280 and 281:
Background - Skin Substitutes • S
- Page 282 and 283:
Background - Skin Substitutes • T
- Page 284 and 285:
Key Questions 1. What is comparativ
- Page 286 and 287:
Evidence Sources • Medline search
- Page 288 and 289:
Evidence Summary Evidence shows mod
- Page 290 and 291:
Public Comment • Submitted by Sol
- Page 292 and 293:
Late breaking studies • Late brea
- Page 294 and 295:
Prerequisites • Based on combinat
- Page 296 and 297:
RATIONALE FOR GUIDANCE DEVELOPMENT
- Page 298 and 299:
Coverage question: Should Apligraf
- Page 300 and 301:
Dermagraft® Coverage question: Sho
- Page 302 and 303:
OASIS® Wound Matrix Coverage quest
- Page 304 and 305:
Coverage question: Should EpiFix®
- Page 306 and 307:
Coverage question: Should Graftjack
- Page 308 and 309:
TheraSkin® Coverage question: Shou
- Page 310 and 311:
tissue and replace the wound with f
- Page 312 and 313:
Products derived from human donor t
- Page 314 and 315:
o Multilayered compression therapy
- Page 316 and 317:
Table 3. Summary of Included Random
- Page 318 and 319:
The prescribing information contain
- Page 320 and 321:
Important Outcome: Adverse Effects
- Page 322 and 323:
Critical Outcome: Quality of Life N
- Page 324 and 325:
infection, and response to usual ca
- Page 326 and 327:
leeding surface wounds, abrasions,
- Page 328 and 329:
group developed an infection in ano
- Page 330 and 331:
illuminate the comparative effectiv
- Page 332 and 333:
Other considerations Expert input a
- Page 334 and 335:
leg ulcers, but do not provide reco
- Page 336 and 337:
pe=All&PolicyType=Final&s=All&KeyWo
- Page 338 and 339:
Coverage guidance is prepared by th
- Page 340 and 341:
Low: The subcommittee’s confidenc
- Page 342 and 343:
Indication No. of Studies Study Des
- Page 344 and 345:
Indication Adverse Effects No. of S
- Page 346 and 347:
Adverse Effects DFU 1 RCT High Unkn
- Page 348 and 349:
Abbreviations: DFU - diabetic foot
- Page 350 and 351:
OASIS® versus Dermagraft® Indicat
- Page 352 and 353:
substitute,” or “bioengineered
- Page 354 and 355:
APPENDIX D. APPLICABLE CODES CODES
- Page 356 and 357:
Q4146 Q4147 Q4148 Q4149 Q4150 Q4151
- Page 358 and 359:
APPENDIX E: FREQUENCY OF APPLICATIO
- Page 360 and 361:
CG-Skin substitutes for diabetic fo
- Page 362 and 363:
CG-Skin substitutes for diabetic fo
- Page 364 and 365:
CG-Skin substitutes for diabetic fo
- Page 366 and 367:
Public Comments HERC Coverage Guida
- Page 368 and 369:
HERC Coverage Guidance - Skin Subst
- Page 370 and 371:
HERC Coverage Guidance - Skin Subst
- Page 372 and 373:
HERC Coverage Guidance - Skin Subst
- Page 374 and 375:
Bariatric Surgery Draft Coverage Gu
- Page 376 and 377:
Background - Obesity • Obesity is
- Page 378 and 379:
Background - Treatments • Structu
- Page 380 and 381:
Background - Surgery Vertical sleev
- Page 382 and 383:
Background - Surgery • Biliopancr
- Page 384 and 385:
Background - Surgery 2011 2012 2013
- Page 386 and 387:
Key Questions 1. Should coverage be
- Page 388 and 389:
Evidence Strengths and Limitations
- Page 390 and 391:
Evidence Review - Adults • WA HTA
- Page 392 and 393:
Evidence Review - Adults • Chang
- Page 394 and 395:
Evidence Review - Adults • Kwok (
- Page 396 and 397:
Evidence Summary - Adults • Baria
- Page 398 and 399:
Evidence Summary - Adults • Harms
- Page 400 and 401:
Evidence Summary - Reoperation •
- Page 402 and 403:
Evidence Review - Children • Gene
- Page 404 and 405:
Evidence Review - Children • Blac
- Page 406 and 407:
Evidence Summary - Children • Bar
- Page 408 and 409:
HEALTH EVIDENCE REVIEW COMMISSION (
- Page 410 and 411:
GRADE‐INFORMED FRAMEWORK The HERC
- Page 412 and 413:
Coverage question: Should bariatric
- Page 414 and 415:
Coverage question: Should bariatric
- Page 416 and 417:
EVIDENCE OVERVIEW Clinical backgrou
- Page 418 and 419:
These procedures can be performed l
- Page 420 and 421:
Critical outcomes selected for incl
- Page 422 and 423:
Systematic Review (Quality) Total N
- Page 424 and 425:
Kwok (2014) Kwok et al. (2014) is a
- Page 426 and 427:
ias were included. The average base
- Page 428 and 429:
Thirteen of the included studies (a
- Page 430 and 431:
Mahawar, Graham, Carr, Jennings, Sc
- Page 432 and 433:
primary). Quantitative cumulative o
- Page 434 and 435:
Thomas (2012) Thomas & Agarwal (201
- Page 436 and 437:
EVIDENCE SUMMARY Despite the existe
- Page 438 and 439:
Bariatric surgery for children is a
- Page 440 and 441:
POLICY LANDSCAPE SOURCES Quality me
- Page 442 and 443:
Non‐Covered Procedures Aetna, Cig
- Page 444 and 445:
Black, J. A., White, B., Viner, R.
- Page 446 and 447:
Fitch, A., Fox, C., Bauerly, K., Gr
- Page 448 and 449:
APPENDIX A. METHODS Scope Statement
- Page 450 and 451:
United States Preventive Services T
- Page 452 and 453:
Low: The subcommittee’s confidenc
- Page 454 and 455:
Quality Assessment (Confidence in E
- Page 456 and 457:
APPENDIX D. MORTALITY BENEFIT OUTCO
- Page 458 and 459:
Johnson (2013) Retrospective cohort
- Page 460 and 461:
APPENDIX E. BARIATRIC SURGERY COVER
- Page 462 and 463:
Table E2. Bariatric Surgery Coverag
- Page 464 and 465:
Table E3. Pre‐Surgical Requiremen
- Page 466 and 467:
(BPD/DS) for individuals with a BMI
- Page 468 and 469:
Table E5. Repeat Surgery Coverage P
- Page 470 and 471:
Distal gastric bypass (long limb ga
- Page 472 and 473:
45.51 Isolation of segment of small
- Page 474 and 475:
APPENDIX G. OUTCOMES BY BASELINE ME
- Page 476 and 477:
APPENDIX H. COST‐EFFECTIVENESS ES
- Page 478 and 479:
GUIDELINE NOTE 8, BARIATRIC SURGERY
- Page 480 and 481:
Bariatric/Metabolic Surgery for Obe
- Page 482 and 483:
Bariatric/Metabolic Surgery for Obe
- Page 484 and 485:
Bariatric/metabolic surgery for obe
- Page 486 and 487:
Bariatric/metabolic surgery for obe
- Page 488 and 489:
Bariatric/metabolic surgery for obe